Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2001-05-17
2008-11-25
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
C435S325000
Reexamination Certificate
active
07455846
ABSTRACT:
The present invention relates various compositions having an immunostimulatory molecule and animal cells cultured in the presence of at least one interferon (IFN) of type I or type II for time and conditions sufficient to enhance the antigen presenting function of the cells. Other aspects of the present invention include methods of treatment and/or prophylaxis of a disease or condition using these immunopotentiating compositions.
REFERENCES:
patent: 5711425 (1998-01-01), Trimble-Gomez
patent: 5858776 (1999-01-01), Ostrand-Rosenberg et al.
patent: 5993828 (1999-11-01), Morton
patent: 6039941 (2000-03-01), Blankenstein et al.
patent: 6183734 (2001-02-01), Chen et al.
patent: 6207170 (2001-03-01), Popescu et al.
patent: 6218371 (2001-04-01), Krieg et al.
patent: 6277368 (2001-08-01), Hiserodt et al.
patent: 6319709 (2001-11-01), Ostrand-Rosenberg et al.
patent: 6451305 (2002-09-01), Boussiotis et al.
patent: 6828150 (2004-12-01), Cai et al.
patent: 7011833 (2006-03-01), Sturmhoefel et al.
patent: 2001/0012517 (2001-08-01), Popescu et al.
patent: 2002/0034500 (2002-03-01), Levings et al.
patent: 2002/0155135 (2002-10-01), Popescu et al.
patent: 2003/0092177 (2003-05-01), Belardelli et al.
patent: 1067194 (2001-01-01), None
patent: 1291414 (2003-03-01), None
patent: WO 94/21808 (1994-09-01), None
patent: WO 97/00085 (1997-01-01), None
patent: WO 98/23728 (1998-06-01), None
patent: WO 99/15199 (1999-04-01), None
patent: WO 99/61051 (1999-12-01), None
patent: WO 00/04918 (2000-02-01), None
patent: WO 00/31138 (2000-06-01), None
patent: WO 00/44880 (2000-08-01), None
patent: WO 01/15728 (2001-03-01), None
patent: WO 01/95919 (2001-12-01), None
patent: WO 02/36769 (2002-05-01), None
patent: WO 03/045427 (2003-06-01), None
Dezfoul et al., Immunol. Cell Biol., 2003, 81: 459-471 (reference provided by Applicant).
Wong et al., Journal of Immunology, 1998, 160: 5475-5484.
Allison et al., Current Opinion in Immunology, 1995, 7: 682-686.
Guo et al., Science, 1994, 263: 518-520.
Bowie et al., Science, 247:1306-1310.
Greenwand et al., 2005, Annu. Rev. Immunol., 23: 515-548.
Attwood T., Science 2000; 290:471-473.
Skolnick et al., Trends in Biotech. 2000; 18(1):34-39.
Honglian et al., “Induction of anti-hepatoma immunity by recombinant retrovirus expressing B7-1/B7-2 costimulatory molecules”,J Med Coll PLA, vol. 15(2), 2000: pp. 138-142.
Kim et al., “Therapeutic anti-tumor response induced with epitope-pulsed fibroblasts genetically engineered for b7.1 expression and IFN-γ sectertion”,Int. J. Cancer, vol. 87, 2000: pp. 427-433.
Lasek et al., “Antitumor effects of the combination therapy with TNF-α gene-modified tumor cells and interleukin 12 in a melanoma model in mice”,Cancer Gene Therapy, vol. 7, No. 12, 2000: pp. 1581-1590.
Lin et al., “Considerations Regarding the Use of Cytokines in Active Specific Immunotherapy of Cancer”,Vaccine Research, vol. 5, No. 1, 1996: pp. 41-48.
Meyer et al., “Potential of CD80-transfected human breast carcinoma cells to induce peptide-specific T lymphocytes in an allogeneic human histocompatibility leukocyte antigens (HLA)-A2.1+- matched situation”,Cancer Gene Therapy, vol. 6, No. 3, 1999: pp. 282-288.
Abril et al.,(1998) “Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line,”Cancer Immunol. Immunother47:113-120.
Aman et al., (1990) “An Epstein-Barr virus immortalization associated gene segment interferes specifically with the IFN-induced anti-proliferative response in human B-lymphoid cell lines,”EMBO9:147-152.
Baltz, J., (1995) “Vaccines in the treatment of cancer,”Am. J. Health-Syst. Phar., 52:2574-2585.
Billard et al., (1986) “Treatment of hairy cell leukemia with recombinant alpha interferon: II. In vivo down-regulation of alpha interferon receptors on tumor cells,”Blood67:821-826.
Bohm et al., (1998) “T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas1”,J. Immunol. 161:897-908.
Cavallo et al., (1995) “Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response,”Eur. J. Immunol. 25:1154-1162.
Chen et al., (1993) “Costimulation of T cells for tumor immunity,”Immunol Today14:483-485.
Chen et al., (1994) “Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity,”J. Exp. Med. 179:523-532.
Chin et al., (1996) “Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21WAF1/CIP1mediated by STAT1,”Science272:719-722.
Chin et al., (1997) “Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis,”Mol. Cell. Biol. 17: 5328-5337.
Colamonici et al., (1992) “Correlation between interferon (IFN) α resistance and deletion of the IFN α/β genes in acute leukemia cell lines suggests selection against the IFN system,”Blood80: 744-749.
Coligan, J.E. et al., (1993) “In vitro assays for mouse lymphocyte function,” Chapt. 3 inCurrent Protocols in Immunology, Edited by Coligan et al., Greene Pub. Associates and Wiley-Interscience, New York. 3.0.1-3.15.12.
De Maeyer et al., (1988) “Induction of IFN-α and IFN-β”, Chapter 3 of Interferons and other regulatory cytokines,John Wiley&Sons, New York, New York, pp. 39-66.
De Maeyer et al., (1988) “The effects of interferons on cell growth and division”, Chapter 7 of Interferons and other regulatory cytokines,John Wiley&Sons, New York, New York, pp. 134-153.
De Maeyer et al., (1988) “The effects of interferons on tumor cells”, Chapter 14 of Interferons and other regulatory cytokines,John Wiley&Sons, New York, New York, pp. 334-363.
Dols et al., (2003) “Allogeneic breast cancer cell vaccines,”Clin. Breast Cancer Suppl. 3: 173-180.
Dron et al., (1993) “Interferon-resistant Daudi cells are deficient in interferon-α-induced ISGF3α activation, but remain sensitive to the interferon-α-induced increase in ISGF3γ content,”J. Interferon Res. 13:377-383.
Gutterman, J. (1994) “Cytokine therapeutics: lessons from interferon α,”PNAS USA., 91:1198-1205.
Haque et al., (1998) “Signal transduction in the interferon system,”Semin. Oncol. 25:14-22.
Hersey et al., (1994) “Expression of the co-stimulatory molecule B7 on melanoma cells,”Int. J. Cancer58:527-532.
Hertzog et al., (1988) “Interferons in rheumatoid arthritis: alterations in production and response related to disease activity,”Clin. Immunol. Immunopathol., 48:192-201.
Heyman et al., (1994) “Interferon system defects in malignant T-cells,”Leukemia8:425-434.
Hsueh et al., (2002) “Active immunotherapy by reinduction with a polyvalent allergeneic cell vaccine correlates with improved survival in recurrent monastic melanoma,”Ann Surg Oncol9: 486-492.
Isaacs et al., (1957) “Virus interference. I. The interferon,”Proc. R. Soc. Lond. (Biol.) 147:258-267.
Johns et al., (1992) “Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon β,”J. Natl. Cancer Inst. 84:1185-1120.
Kanda et al., (1992) “The EBNA2-related resistance towards alpha interferon (IFN-α) in Burkitt's lymphoma cells effects induction of IFN-induced genes but not the activation of transcription factor ISGF-3,”Mol. Cel. Biol. 12:4930-4936.
Kaplan et al., (1998) “Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice,”PNAS USA95:7556-7561.
Kolla et al., (1996) “Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up regulation of STAT1 protein in IFN-unresponsive cells,”J. Biol. Chem. 271:10508-10514.
Kuniyasu et al., (1997) “Growth inhibitory effect of inte
Knobbe Martens Olson & Bear LLP
Ouspenski Ilia
Ralph Stephen John
LandOfFree
Immune potentiating compositions of cancer cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immune potentiating compositions of cancer cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immune potentiating compositions of cancer cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4042855